Chidamide in Combination With <scp>DCAG</scp> With or Without Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia
In conclusion, venetoclax in combination with CDCAG is an effective and safe treatment regimen for R/R AML, thereby rapidly identifying chemosensitive patients and inducing measurable residual disease-negative remission in a high proportion of patients with R/R AML.
Authors
- Xiawei Zhang (ORCID: https://orcid.org/0000-0003-4070-9228)
- Liping Dou (ORCID: https://orcid.org/0000-0001-7352-9560)
- Lili Wang (ORCID: https://orcid.org/0000-0003-2308-7404)
- Wenjing Gao (ORCID: https://orcid.org/0009-0004-1368-3610)
- Lin Xu (ORCID: https://orcid.org/0000-0002-2153-4840)
- Qingyang Liu (ORCID: https://orcid.org/0009-0002-8535-7203)
- Jing Yu (ORCID: https://orcid.org/0000-0003-4372-1353)
- Lei Lv
Institutions
- Chinese PLA General Hospital (CN)
- PLA Academy of Military Science (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1002/cam4.70734
- Citations
- 2
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 3.54